| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 10 | 2024 | 598 | 1.410 |
Why?
|
| Dabigatran | 7 | 2024 | 26 | 1.280 |
Why?
|
| Warfarin | 4 | 2014 | 124 | 1.220 |
Why?
|
| Venous Thromboembolism | 6 | 2024 | 178 | 0.870 |
Why?
|
| Camptothecin | 4 | 2008 | 77 | 0.760 |
Why?
|
| Blood Coagulation | 4 | 2022 | 129 | 0.520 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2007 | 110 | 0.500 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2019 | 197 | 0.500 |
Why?
|
| Child, Preschool | 35 | 2022 | 14776 | 0.490 |
Why?
|
| International Normalized Ratio | 2 | 2013 | 44 | 0.470 |
Why?
|
| Fibrinolytic Agents | 1 | 2016 | 204 | 0.460 |
Why?
|
| Neoplasms | 9 | 2008 | 3025 | 0.430 |
Why?
|
| Child | 43 | 2024 | 25712 | 0.420 |
Why?
|
| Hospital Information Systems | 1 | 2013 | 46 | 0.410 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2013 | 1159 | 0.400 |
Why?
|
| Postoperative Hemorrhage | 1 | 2013 | 84 | 0.390 |
Why?
|
| Heart-Assist Devices | 3 | 2016 | 1093 | 0.390 |
Why?
|
| Adolescent | 34 | 2022 | 20517 | 0.380 |
Why?
|
| Methotrexate | 3 | 2019 | 355 | 0.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 809 | 0.350 |
Why?
|
| Infant | 25 | 2022 | 13135 | 0.340 |
Why?
|
| Blood Coagulation Factor Inhibitors | 1 | 2010 | 2 | 0.340 |
Why?
|
| Thrombosis | 2 | 2014 | 537 | 0.340 |
Why?
|
| Factor V | 1 | 2010 | 18 | 0.340 |
Why?
|
| Thrombin | 1 | 2010 | 62 | 0.330 |
Why?
|
| Hemostatics | 1 | 2010 | 63 | 0.320 |
Why?
|
| Acyclovir | 2 | 2009 | 47 | 0.320 |
Why?
|
| Antineoplastic Agents | 6 | 2009 | 1850 | 0.320 |
Why?
|
| Patient Readmission | 1 | 2013 | 412 | 0.320 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2006 | 104 | 0.310 |
Why?
|
| Meningeal Neoplasms | 3 | 2007 | 220 | 0.300 |
Why?
|
| Valine | 1 | 2008 | 116 | 0.290 |
Why?
|
| Body Mass Index | 1 | 2014 | 1709 | 0.290 |
Why?
|
| Drug Resistance | 1 | 2008 | 263 | 0.280 |
Why?
|
| Obesity | 3 | 2014 | 2410 | 0.280 |
Why?
|
| Secondary Prevention | 4 | 2024 | 225 | 0.270 |
Why?
|
| Male | 42 | 2022 | 65815 | 0.270 |
Why?
|
| Female | 41 | 2022 | 71584 | 0.260 |
Why?
|
| Aspirin | 1 | 2008 | 231 | 0.260 |
Why?
|
| Sesquiterpenes | 1 | 2006 | 26 | 0.260 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 304 | 0.260 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 896 | 0.240 |
Why?
|
| Drug Administration Schedule | 7 | 2010 | 755 | 0.240 |
Why?
|
| Pharmacogenetics | 2 | 2010 | 196 | 0.240 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2022 | 83 | 0.240 |
Why?
|
| Antithrombins | 3 | 2022 | 57 | 0.230 |
Why?
|
| Cytarabine | 1 | 2004 | 100 | 0.230 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 447 | 0.220 |
Why?
|
| Humans | 49 | 2024 | 133849 | 0.220 |
Why?
|
| Maximum Tolerated Dose | 5 | 2007 | 173 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2021 | 1354 | 0.200 |
Why?
|
| Thrombophilia | 1 | 2022 | 43 | 0.200 |
Why?
|
| Doxorubicin | 2 | 2008 | 302 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2021 | 15 | 0.190 |
Why?
|
| Receptors, Fc | 2 | 2011 | 33 | 0.180 |
Why?
|
| Thrombopoietin | 2 | 2011 | 33 | 0.180 |
Why?
|
| Protein C Deficiency | 2 | 2022 | 12 | 0.180 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 17 | 0.180 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2011 | 50 | 0.180 |
Why?
|
| Topotecan | 1 | 2001 | 50 | 0.180 |
Why?
|
| Sarcoma, Ewing | 1 | 2021 | 117 | 0.170 |
Why?
|
| Hemorrhage | 3 | 2017 | 507 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 801 | 0.140 |
Why?
|
| Arabinonucleosides | 2 | 2009 | 33 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 607 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 1409 | 0.140 |
Why?
|
| Treatment Outcome | 11 | 2017 | 13011 | 0.130 |
Why?
|
| Risk Factors | 6 | 2022 | 11077 | 0.130 |
Why?
|
| Partial Thromboplastin Time | 2 | 2022 | 48 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2018 | 128 | 0.130 |
Why?
|
| Administration, Oral | 3 | 2020 | 730 | 0.130 |
Why?
|
| Purpura Fulminans | 1 | 2016 | 7 | 0.130 |
Why?
|
| Protein C | 1 | 2016 | 21 | 0.130 |
Why?
|
| Ultraviolet Rays | 1 | 1997 | 215 | 0.130 |
Why?
|
| Leukemia, Myeloid | 2 | 2009 | 82 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1997 | 136 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1735 | 0.120 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 169 | 0.120 |
Why?
|
| Thromboembolism | 1 | 2016 | 91 | 0.120 |
Why?
|
| Rhabdomyosarcoma | 1 | 2018 | 209 | 0.120 |
Why?
|
| Models, Biological | 2 | 2019 | 1533 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 186 | 0.120 |
Why?
|
| Institutional Practice | 1 | 2014 | 6 | 0.120 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2014 | 5 | 0.110 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2008 | 282 | 0.110 |
Why?
|
| Fibrinolysin | 1 | 2014 | 13 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2014 | 38 | 0.110 |
Why?
|
| Adult | 15 | 2021 | 31925 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2016 | 6655 | 0.110 |
Why?
|
| Osteosarcoma | 1 | 2016 | 263 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2013 | 32 | 0.100 |
Why?
|
| Citalopram | 1 | 2013 | 30 | 0.100 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 151 | 0.100 |
Why?
|
| Levofloxacin | 1 | 2013 | 47 | 0.100 |
Why?
|
| Factor Xa | 1 | 2012 | 17 | 0.100 |
Why?
|
| Methyltransferases | 2 | 2005 | 82 | 0.100 |
Why?
|
| Leukemia | 2 | 2007 | 380 | 0.100 |
Why?
|
| Enoxaparin | 1 | 2012 | 43 | 0.100 |
Why?
|
| Adenine Nucleotides | 2 | 2009 | 41 | 0.100 |
Why?
|
| Heart Failure, Systolic | 1 | 2012 | 36 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1874 | 0.090 |
Why?
|
| Factor Xa Inhibitors | 1 | 2012 | 66 | 0.090 |
Why?
|
| Recurrence | 4 | 2022 | 1467 | 0.090 |
Why?
|
| Thrombopoiesis | 1 | 2011 | 12 | 0.090 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2011 | 31 | 0.090 |
Why?
|
| Medulloblastoma | 2 | 2007 | 570 | 0.090 |
Why?
|
| Injections, Spinal | 3 | 2007 | 136 | 0.090 |
Why?
|
| Glucuronosyltransferase | 2 | 2008 | 72 | 0.090 |
Why?
|
| Prothrombin Time | 1 | 2010 | 36 | 0.080 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2014 | 640 | 0.080 |
Why?
|
| Blood Coagulation Tests | 2 | 2022 | 63 | 0.080 |
Why?
|
| Venoms | 1 | 2010 | 20 | 0.080 |
Why?
|
| Time Factors | 3 | 2020 | 6584 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2014 | 833 | 0.080 |
Why?
|
| Infant, Newborn | 6 | 2018 | 8576 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2016 | 17456 | 0.080 |
Why?
|
| Age Factors | 3 | 2017 | 2975 | 0.080 |
Why?
|
| 2-Aminopurine | 1 | 2009 | 4 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 862 | 0.080 |
Why?
|
| Chickenpox | 1 | 2009 | 22 | 0.080 |
Why?
|
| Herpesvirus 3, Human | 1 | 2009 | 30 | 0.080 |
Why?
|
| Cattle | 1 | 2010 | 588 | 0.080 |
Why?
|
| Simplexvirus | 1 | 2009 | 107 | 0.080 |
Why?
|
| Epidemiologic Measurements | 1 | 2008 | 3 | 0.080 |
Why?
|
| Herpes Simplex | 1 | 2009 | 57 | 0.070 |
Why?
|
| Hypoglycemic Agents | 2 | 2010 | 479 | 0.070 |
Why?
|
| Glucuronates | 1 | 2008 | 8 | 0.070 |
Why?
|
| Endpoint Determination | 2 | 2020 | 59 | 0.070 |
Why?
|
| Platelet Aggregation | 1 | 2008 | 125 | 0.070 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NAD+) | 1 | 2007 | 3 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 764 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1334 | 0.070 |
Why?
|
| Antitussive Agents | 1 | 2007 | 3 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2007 | 84 | 0.070 |
Why?
|
| Dextromethorphan | 1 | 2007 | 11 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2007 | 48 | 0.070 |
Why?
|
| Pyrazines | 1 | 2007 | 73 | 0.070 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 971 | 0.060 |
Why?
|
| Peptides | 1 | 2010 | 861 | 0.060 |
Why?
|
| Busulfan | 1 | 2006 | 45 | 0.060 |
Why?
|
| Body Composition | 1 | 2008 | 563 | 0.060 |
Why?
|
| Meningitis | 1 | 2006 | 101 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2012 | 894 | 0.060 |
Why?
|
| Acute Disease | 3 | 2020 | 1189 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2007 | 184 | 0.060 |
Why?
|
| Glucagon | 1 | 2005 | 184 | 0.060 |
Why?
|
| Blood Glucose | 2 | 2010 | 1193 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2007 | 236 | 0.060 |
Why?
|
| Amyloid | 1 | 2005 | 70 | 0.060 |
Why?
|
| Spinal Puncture | 1 | 2004 | 53 | 0.060 |
Why?
|
| Hospitalization | 2 | 2011 | 1884 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2017 | 181 | 0.050 |
Why?
|
| Liposomes | 1 | 2004 | 206 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 142 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 1139 | 0.050 |
Why?
|
| Area Under Curve | 4 | 2008 | 333 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2009 | 822 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2004 | 234 | 0.050 |
Why?
|
| Glioma | 2 | 2006 | 537 | 0.050 |
Why?
|
| Folic Acid | 1 | 2005 | 298 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1201 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2021 | 702 | 0.050 |
Why?
|
| Mitoxantrone | 1 | 2002 | 27 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 3 | 2008 | 145 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 77 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1314 | 0.050 |
Why?
|
| Etoposide | 1 | 2002 | 120 | 0.050 |
Why?
|
| Survival Rate | 2 | 2020 | 2207 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2002 | 148 | 0.050 |
Why?
|
| Azathioprine | 1 | 2001 | 56 | 0.050 |
Why?
|
| Phenylacetates | 1 | 2001 | 23 | 0.050 |
Why?
|
| Quality of Life | 1 | 2011 | 2132 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 2654 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2515 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2001 | 153 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2001 | 72 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2001 | 66 | 0.040 |
Why?
|
| Homeostasis | 1 | 2005 | 748 | 0.040 |
Why?
|
| Phenylbutyrates | 1 | 2001 | 58 | 0.040 |
Why?
|
| Infusions, Intravenous | 3 | 2008 | 571 | 0.040 |
Why?
|
| Aging | 1 | 2007 | 1304 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2008 | 3738 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2001 | 235 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1153 | 0.040 |
Why?
|
| Dactinomycin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Drug Compounding | 1 | 2017 | 43 | 0.040 |
Why?
|
| Vincristine | 1 | 2018 | 196 | 0.040 |
Why?
|
| Benzoic Acid | 1 | 1997 | 3 | 0.030 |
Why?
|
| Benzoates | 1 | 1997 | 23 | 0.030 |
Why?
|
| Catalase | 1 | 1997 | 69 | 0.030 |
Why?
|
| Young Adult | 4 | 2016 | 9885 | 0.030 |
Why?
|
| Riboflavin | 1 | 1997 | 41 | 0.030 |
Why?
|
| Body Weight | 1 | 2021 | 1034 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 1997 | 82 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2011 | 1667 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1997 | 239 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 418 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1997 | 187 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 68 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 356 | 0.030 |
Why?
|
| Cell Division | 1 | 1997 | 774 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1997 | 1102 | 0.030 |
Why?
|
| Genotype | 3 | 2007 | 2807 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 1995 | 74 | 0.030 |
Why?
|
| Animals | 3 | 2010 | 36363 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2012 | 3638 | 0.030 |
Why?
|
| Prothrombin | 1 | 2014 | 27 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2014 | 26 | 0.030 |
Why?
|
| Fibrinolysis | 1 | 2014 | 42 | 0.030 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1995 | 140 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 1197 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1995 | 298 | 0.030 |
Why?
|
| Heparin | 1 | 2014 | 226 | 0.020 |
Why?
|
| Parents | 2 | 2011 | 1058 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2011 | 132 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 5173 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2002 | 364 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2012 | 244 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5505 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 21 | 0.020 |
Why?
|
| Postprandial Period | 1 | 2010 | 91 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2011 | 275 | 0.020 |
Why?
|
| Nausea | 1 | 2009 | 86 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2012 | 710 | 0.020 |
Why?
|
| Remission Induction | 1 | 2009 | 308 | 0.020 |
Why?
|
| Folic Acid Antagonists | 1 | 2007 | 17 | 0.020 |
Why?
|
| Neutropenia | 1 | 2009 | 201 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 60 | 0.020 |
Why?
|
| Dealkylation | 1 | 2007 | 4 | 0.020 |
Why?
|
| Bilirubin | 1 | 2008 | 131 | 0.020 |
Why?
|
| Biotransformation | 1 | 2007 | 55 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 290 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2007 | 61 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2007 | 34 | 0.020 |
Why?
|
| United States | 1 | 2022 | 11682 | 0.020 |
Why?
|
| Bortezomib | 1 | 2007 | 72 | 0.020 |
Why?
|
| Fever | 1 | 2009 | 309 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2007 | 317 | 0.020 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2006 | 18 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 142 | 0.020 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2006 | 57 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2007 | 271 | 0.020 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2005 | 13 | 0.010 |
Why?
|
| Survivors | 1 | 2007 | 360 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 866 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 87 | 0.010 |
Why?
|
| Thalidomide | 1 | 2004 | 41 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 1386 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2007 | 482 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 820 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 3422 | 0.010 |
Why?
|
| Ependymoma | 1 | 2006 | 174 | 0.010 |
Why?
|
| Hypoglycemia | 1 | 2005 | 193 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 2005 | 242 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 51 | 0.010 |
Why?
|
| Alleles | 1 | 2007 | 1706 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 261 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2001 | 54 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 1188 | 0.010 |
Why?
|
| Insulin | 1 | 2005 | 1246 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2001 | 514 | 0.010 |
Why?
|
| Mice | 1 | 1997 | 18883 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 5070 | 0.010 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2001 | 216 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 3987 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 3476 | 0.010 |
Why?
|
| Phenotype | 1 | 2001 | 4532 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 29371 | 0.000 |
Why?
|